
HROW Stock Forecast & Price Target
HROW Analyst Ratings
Bulls say
Harrow is supported by a strengthened commercial model that is already translating into growth, with 3Q26 revenue of $99.3M up 39% YoY and branded revenue of $83.5M, or about 84% of the total, driven by VEVYE, IHEEZO, and early BYOOVIZ traction. The investment case is reinforced by product-level differentiation and cross-selling leverage: VEVYE posted record quarterly revenue of $39.7M, IHEEZO showed a 58% reduction in discomfort in its randomized study and 65,477 record units in 2Q, and TYRVAYA adds a complementary dry-eye mechanism while expanding prescriber reach in 4Q26. With a broader ophthalmology platform, an 18-product portfolio, and a credible path toward 2026 revenue guidance of $350M-$365M and 2027 quarterly revenue aspirations, the company appears well positioned to compound growth through commercialization and pipeline optionality.
Bears say
Harrow is facing a negative fundamental setup because its reported progress is being masked by heavy execution and reimbursement risk, with 1H’26 revenue of $114.9MM still requiring a very steep 2H’26 ramp to reach management’s $350M–$365M target. The company’s profitability outlook weakened materially when 2026 Adjusted EBITDA guidance was cut to more than $40M from $80M–$100M, even as accounts receivable reached $155.3M versus $75.3M in cash and equivalents as of September 30, 2026. Structural pressures in TRIESENCE, IHEEZO, and VEVYE remain significant, including entrenched cheap generics, payer pushback, and the April 1, 2026 loss of IHEEZO’s ASC pass-through, which could constrain both growth and margins.
This aggregate rating is based on analysts' research of Harrow Health Inc and is not a guaranteed prediction by Public.com or investment advice.
HROW Analyst Forecast & Price Prediction
Start investing in HROW
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Harrow Health Inc (HROW) Forecast
HROW Analyst Forecast & Price Prediction
Start investing in HROW
Order type
Buy in
Order amount
Est. shares
0 shares